Pulmatrix, headquartered in FRAMINGHAM, Mass., is showing ongoing support for Cullgen in their efforts to gain approval for their merger from the China Securities Regulatory Commission. The merger involves Pulmatrix, Inc. (Nasdaq: PULM), a biopharmaceutical firm that concentrates on specialized drug delivery platforms. The collaboration aims to combine resources, with significant financial implications as highlighted by the stock exchange listing on Nasdaq.